Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma.
Our Guest
Dr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.
This podcast episode was sponsored by Pfizer Canada Inc.
If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).
Pas encore de commentaire